Literature DB >> 16525167

Apparent and internal validity of a Monte Carlo-Markov model for cardiovascular disease in a cohort follow-up study.

Rogier L Nijhuis1, Theo Stijnen, Anna Peeters, Jacqueline C M Witteman, Albert Hofman, M G Myriam Hunink.   

Abstract

OBJECTIVE: To determine the apparent and internal validity of the Rotterdam Ischemic heart disease & Stroke Computer (RISC) model, a Monte Carlo-Markov model, designed to evaluate the impact of cardiovascular disease (CVD) risk factors and their modification on life expectancy (LE) and cardiovascular disease-free LE (DFLE) in a general population (hereinafter, these will be referred to together as (DF)LE).
METHODS: The model is based on data from the Rotterdam Study, a cohort follow-up study of 6871 subjects aged 55 years and older who visited the research center for risk factor assessment at baseline (1990-1993) and completed a follow-up visit 7 years later (original cohort). The transition probabilities and risk factor trends used in the RISC model were based on data from 3501 subjects (the study cohort). To validate the RISC model, the number of simulated CVD events during 7 years' follow-up were compared with the observed number of events in the study cohort and the original cohort, respectively, and simulated (DF)LEs were compared with the (DF)LEs calculated from multistate life tables.
RESULTS: Both in the study cohort and in the original cohort, the simulated distribution of CVD events was consistent with the observed number of events (CVD deaths: 7.1% v. 6.6% and 7.4% v. 7.6%, respectively; non-CVD deaths: 11.2% v. 11.5% and 12.9% v. 13.0%, respectively). The distribution of (DF)LEs estimated with the RISC model consistently encompassed the (DF)LEs calculated with multistate life tables.
CONCLUSIONS: The simulated events and (DF)LE estimates from the RISC model are consistent with observed data from a cohort follow-up study.

Entities:  

Mesh:

Year:  2006        PMID: 16525167     DOI: 10.1177/0272989X05284103

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  6 in total

1.  Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.

Authors:  Ankur Pandya; Stephen Sy; Sylvia Cho; Sartaj Alam; Milton C Weinstein; Thomas A Gaziano
Journal:  Med Decis Making       Date:  2017-05-10       Impact factor: 2.583

2.  A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation.

Authors:  J D Lewsey; K D Lawson; I Ford; K A A Fox; L D Ritchie; H Tunstall-Pedoe; G C M Watt; M Woodward; S Kent; M Neilson; A H Briggs
Journal:  Heart       Date:  2014-10-16       Impact factor: 5.994

3.  Comparison of the flexible parametric survival model and Cox model in estimating Markov transition probabilities using real-world data.

Authors:  Xudong Du; Mier Li; Ping Zhu; Ju Wang; Lisha Hou; Jijie Li; Hongdao Meng; Muke Zhou; Cairong Zhu
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

4.  Performance evaluation of survival regression models in analysing Swedish dental implant complication data with frailty.

Authors:  Adeniyi Francis Fagbamigbe; Karolina Karlsson; Jan Derks; Max Petzold
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

5.  Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model.

Authors:  Bob J H van Kempen; Bart S Ferket; Albert Hofman; Ewout W Steyerberg; Ersen B Colkesen; S Matthijs Boekholdt; Nicholas J Wareham; Kay-Tee Khaw; M G Myriam Hunink
Journal:  BMC Med       Date:  2012-12-06       Impact factor: 8.775

6.  Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.

Authors:  Bart S Ferket; Bob J H van Kempen; Jan Heeringa; Sandra Spronk; Kirsten E Fleischmann; Rogier L G Nijhuis; Albert Hofman; Ewout W Steyerberg; M G Myriam Hunink
Journal:  PLoS Med       Date:  2012-12-27       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.